Business
eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today
Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into ...
About this update from Exozymes Inc.
[{"type":"text","content":"Management to host earnings call at 5:00PM Eastern Time, today.","length":72,"tagName":"p"},{"type":"text","content":"MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal quarter that ended March 31, 2025, as well as the launch of the purpose-built subsidiary, NCTx.","length":414,"tagName":"p"},{"type":"text","content":"Michael Heltzen, CEO of eXoZymes, states, "We have reached our first commercial milestone by launching the NCTx spin-out last week, which we also will cover on today's earnings call. As a pre-revenue company, we remain focused on efficient execution and capital allocation while we make progress towards our value inflection points."","length":347,"tagName":"p"},{"type":"text","content":"First quarter 2025, NCTx launch, and subsequent operational highlights:","length":71,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Commercialization: Launching purpose-built subsidiary, NCTx, to develop and commercialize the eXoZymes platform with the small molecule compound, N-trans-caffeoyltyramine (NCT), marks the first commercial milestone.","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Investment: Operating expenses rose to $1.95 million, primarily due to expanded R&D and leadership hires to drive long-term growth.Ended Q1 2025 with $8.51 million in cash and cash equivalents, supporting operations into 2026.","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"Extraordinary effort: The eXoZymes team continues to perform at a high level, enabling the company to accomplish important milestones.","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":589,"olType":false},{"type":"text","content":"Investors and interested parties can access the live webinar, at the time of the event through eXoZymes' investor relations website. A recording of the conference call will also be made publicly available soon after the live call.","length":234,"tagName":"p"},{"type":"text","content":"Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by sel...